By Application
Hot products 
-
Mouse Anti-BLK Recombinant Antibody (CBYY-0618) (CBMAB-0621-YY)
-
Mouse Anti-DLC1 Recombinant Antibody (D1009) (CBMAB-D1009-YC)
-
Mouse Anti-BANF1 Recombinant Antibody (3F10-4G12) (CBMAB-A0707-LY)
-
Mouse Anti-CD1C Recombinant Antibody (L161) (CBMAB-C2173-CQ)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7697) (CBMAB-1869CQ)
-
Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
-
Mouse Anti-ASB9 Recombinant Antibody (1D8) (CBMAB-A0529-LY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-AMIGO2 Recombinant Antibody (CBYY-C0756) (CBMAB-C2192-YY)
-
Mouse Anti-Acetyl-α-Tubulin (Lys40) Recombinant Antibody (V2-623485) (CBMAB-CP2897-LY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-ADIPOR2 Recombinant Antibody (V2-179983) (CBMAB-A1369-YC)
-
Mouse Anti-AZGP1 Recombinant Antibody (CBWJZ-007) (CBMAB-Z0012-WJ)
-
Mouse Anti-CCS Recombinant Antibody (CBFYC-1093) (CBMAB-C1150-FY)
-
Mouse Anti-CIITA Recombinant Antibody (CBLC160-LY) (CBMAB-C10987-LY)
-
Mouse Anti-B2M Recombinant Antibody (CBYY-0050) (CBMAB-0050-YY)
-
Mouse Anti-ABIN2 Recombinant Antibody (V2-179106) (CBMAB-A0349-YC)
-
Rat Anti-4-1BB Recombinant Antibody (V2-1558) (CBMAB-0953-LY)
-
Mouse Anti-ATM Recombinant Antibody (2C1) (CBMAB-A3970-YC)
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
Prostate Cancer
Fig.1 Prostate cancer
Prostate cancer is regarded as glandular cancer or adenocarcinoma, which starts when normal semen-secreting prostate gland cells mutation happens and changes into cancer cells. The majority of prostate cancers are slow-growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other sites of the body, particularly the lymph nodes and bones. It may initially cause no symptoms. But in later stages it can lead to difficulty urinating, blood in the urine, pain in the pelvis when urinating. The primary risk factors are age, obesity, and family history. Around 99% of cases occur in people over the age of 50 and the average age at the time of diagnosis is around 70. Mutations in BRCA1 and BRCA2 are important risk factors for ovarian cancer and breast cancer in women, have also been implicated in prostate cancer. The expression of Ki-67 by immunohistochemistry may be a significant predictor of patient outcome for men with prostate cancer.
Loading...
Compare
